Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CARLY

Financiado

Development and characterization of a novel CAR T-cell therapy for NHL

Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressive NHL is a combination of chem... ver más

30/06/2027

FUNDACIO INSTITUT...

226K€

Presupuesto del proyecto: 226K€

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM... Actividades de investigación asociacion

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-26

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

FUNDACIO INSTITUT DE RECERCA...

226.44K€ | Lider

ONECHAIN IMMUNOTHERAPEUTICS...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2017-6578-1 Plataformas automáticas de producción de células CAR T para... 136K€ Cerrado

RYC2018-024442-I Chimeric Antigen Receptor (CAR)-modified T cells for the tre... 309K€ Cerrado

PID2021-128283OA-I00 CELULAS CAR-T FRENTE A ANTIGENOS DEL MICROAMBIENTE TUMORAL C... 157K€ Cerrado

PID2019-108989RB-I00 EL MICROAMBIENTE TUMORAL COMO DIANA PARA EL DESARROLLO DE IN... 157K€ Cerrado

CHEMCELL Chemical Engineering of Natural Killer Cells for Cancer Immu... 150K€ Cerrado

CNS2023-143983 Inmunidad, infección e inmunoterapia 200K€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2024-03-26
Fecha Fin: 2027-06-30

Líder del proyecto

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEM... Actividades de investigación asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 226K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughout the body. The standard of care for patients with aggressive NHL is a combination of chemotherapy and immunotherapy. Even though it is well tolerated, ~40% of the patients respond poorly and eventually relapse. Novel personalized treatment options are now available for such individuals and engage patients’ own T cells genetically manipulated to express a chimeric antigen receptor (CAR) capable to recognize and attack malignant cells. Thus far, CAR-T products recognizing and attacking cells expressing the protein CD19 have been approved by regulatory agencies across the planet. However, long-term follow-up studies show that more than half of these patients eventually succumb to relapse after CAR-T treatment. One of the causes for this is the loss of the CD19 protein on NHL cells. Therefore, finding other proteins beyond CD19 that could be targeted or co-targeted with CAR-T-cells is desired. Indeed, in the proposed project, I intend to develop and characterize a CAR-T therapy directed against a cell surface protein highly expressed in NHL (preliminary data). Herein, I plan to evaluate the levels of the new target protein in a large cohort of NHL patients using immunohistochemistry and to perform a thorough preclinical assessment of this novel CAR-T-cell approach using cutting-edge preclinical NHL models. To achieve these goals, I will exploit the experience of the hosting institution in generating NHL patient-derived xenografts and in the bench-to-bedside CAR-T development process, as well as the external collaborators who are experts in blood cancer treatment. This fellowship will significantly expose me to world-class theoretical and hands-on preclinical research in hematooncology and adoptive cell therapy, thus boosting my career as an independent researcher.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores